The latest price and buying guide of Mobotinib (Mobosetinib) in 2024

Mobocertinib (also known as TAK-788), is an innovative oral tyrosine kinase inhibitor (TKI) designed to treat EGFR-bearing Design of patients with non-small cell lung cancer (NSCLC) with exon 20 insertion mutations. This breakthrough medicine provides a new treatment option for patients who do not respond well to traditional EGFR-TKI treatments.

Currently, Mobotinib (Mobosetinib) has been launched in China, but unfortunately it has not yet been included in the medical insurance catalog, resulting in relatively limited domestic purchase channels. For more detailed purchasing information, patients are advised to consult their local hospital pharmacy. In the international market, consumers can choose original drugs or generic drugs. Original drugs, such as the Hong Kong version of products produced by Japan's Takeda Pharmaceutical, are relatively expensive, about 7,000 to 8,000 yuan. Generic drugs, on the other hand, are mainly from Laos and Bangladesh. They are more affordable, about more than 3,000 yuan, and their drug ingredients are highly similar to the original drugs.

Mobotinib has a unique mechanism of action. It selectively inhibits the activity of abnormal EGFR, thereby effectively preventing the growth and spread of cancer cells. This selective effect makes it have a powerful inhibitory effect on tumor cells carrying specific EGFR mutations, while having less impact on normal cells, thus reducing the occurrence of side effects.

Clinical trial data indicate that mobotinib (mobosetinib) has excellent anti-tumor activity. Multiple studies have confirmed that mobosetinib (mobosetinib) has significant efficacy in patients who have previously received chemotherapy or other EGFR-TKI treatments but failed to respond. 2021 data shows that the drug’s overall objective response rate (ORR) and progression-free survival (PFS) have been significantly improved.

Of course, the use of Mobosetinib may also be associated with some side effects, such as diarrhea, rash, nausea and stomatitis, but most of them are mild to moderate. Doctors need to monitor closely and deal with possible serious side effects, such as interstitial lung disease and QT interval prolongation, to ensure patient safety.